LYON, France–(BUSINESS WIRE)–Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC, the “Company”), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of metabolic diseases including diabetes and obesity, today announces the presentation of preclinical data in poster format on its AdoXLong™ platform applied to semaglutide, AdoXL Sema, at ObesityWeek® 2026, taking place in Washington, USA, November 14-